Quick Answer
CUMBERLAND PHARMACEUTICALS INC reported Revenue (ASC 606) of $44.52 million for fiscal year 2025.
CUMBERLAND PHARMACEUTICALS INC Revenue (ASC 606) — Annual History
| Fiscal Year | Revenue (ASC 606) | YoY Change |
|---|---|---|
| 2025 | $44.52M | +17.6% |
| 2024 | $37.87M | -4.3% |
| 2023 | $39.55M | -5.9% |
| 2022 | $42.01M | — |
Quarterly Revenue (ASC 606)
| Quarter Ending | Revenue (ASC 606) | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $8.29M | -8.7% | -23.5% |
| June 30, 2025 | $10.84M | +10.0% | -7.5% |
| March 31, 2025 | $11.71M | +37.8% | +28.9% |
| September 30, 2024 | $9.09M | -9.9% | -7.7% |
| June 30, 2024 | $9.85M | -9.6% | +15.9% |
| March 31, 2024 | $8.50M | -7.9% | -15.7% |
| September 30, 2023 | $10.09M | -11.6% | -7.4% |
| June 30, 2023 | $10.89M | +5.7% | +18.0% |
- CUMBERLAND PHARMACEUTICALS INC showed an increase of +17.6% in Revenue (ASC 606) compared to the prior fiscal year.
- Over the 2022–2025 period, CUMBERLAND PHARMACEUTICALS INC’s revenue (asc 606) has grown by 6.0% (from $42.01 million to $44.52 million).
- The most recent figure is from CUMBERLAND PHARMACEUTICALS INC’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 9, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: